Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene

Growth Hormone and IGF Research

Volumn 20, Issue 1, 2010, Pages 68-72

  Schayek, Hagit ^a   Bentov, Itay ^a   Rotem, Itay ^a   Pasmanik Chor, Metsada ^a   Ginsberg, Doron ^b   Plymate, Stephen R ^c   Werner, Haim ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

E2F1; IGF; IGF I receptor; Transcription factors

Indexed keywords

LUCIFERASE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE CONTROL; GENE DELETION; GENE EXPRESSION REGULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

CELL LINE, TUMOR; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; TRANSCRIPTIONAL ACTIVATION;

EID: 74649085093     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.08.001     Document Type: Article

References (45)

1. Baserga R., and Rubin R. Cell cycle and growth control. Crit. Rev. Eukar. Gene Exp. 3 (1993) 47-61
2. Moschos S.J., and Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63 (2002) 317-332
3. Lu K., and Campisi J. Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts. Proc. Natl. Acad. Sci. USA 89 (1992) 3889-3893
4. Macaulay V.M. Insulin-like growth factors and cancer. Br. J. Cancer 65 (1992) 311-320
5. Ibrahim Y.H., and Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm. IGF Res. 14 (2004) 261-269
6. Bentov I., and Werner H. Insulin-like growth factor-I. In: Kastin A. (Ed). Handbook of Biologically Active Peptides (2006), Elsevier Press, San Diego 1385-1392
7. LeRoith D., Werner H., Beitner-Johnson D., and Roberts Jr. C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16 (1995) 143-163
8. Werner H., and LeRoith D. New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell. Mol. Life Sci. 57 (2000) 932-942
9. Baker J., Liu J.-P., Robertson E.J., and Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75 (1993) 73-82
10. Werner H., and LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res. 68 (1996) 183-223
11. Werner H., and Roberts Jr. C.T. The IGF-I receptor gene: a molecular target for disrupted transcription factors. Gene Chromosome Cancer 36 (2003) 113-120
12. Werner H., and Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol. Metab. 17 (2006) 236-242
13. Yuen J.S.P., Cockman M.E., Sullivan M., Protheroe A., Turner G.D.H., Roberts I.S., Pugh C.W., Werner H., and Macaulay V.M. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26 (2007) 6499-6508
14. Dyson N. The regulation of E2F by pRB-family proteins. Gene Dev. 12 (1998) 2245-2262
15. Cam H., and Dynlacht B.D. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3 (2003) 311-316
16. DeGregori J., and Johnson D.G. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr. Mol. Med. 6 (2006) 739-748
17. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
18. Stanelle J., and Putzer B.M. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol. Med. 12 (2006) 177-185
19. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett. 529 (2002) 122-125
20. Ma Y., Croxton R., Moorer R.L.J., and Cress W.D. Identification of novel E2F1-regulated genes by microarray. Arch. Biochem. Biophys. 399 (2002) 212-224
21. Stanelle J., Stiewe T., Theseling C.C., Peter M., and Putzer B.M. Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 30 (2002) 1859-1867
22. Muller H., Bracken A.P., Vernell R., Moroni M.C., Christians F., Grassilli E., Prosperini E., Vigo E., Oliner J.D., and Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Gene Dev. 15 (2001) 267-285
23. Wolk A., Mantzoros C.S., Andersson S.-O., Bergstrom R., Signorello L.B., Lagiou P., Adami H.O., and Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case control study. J. Natl. Cancer Inst. 90 (1998) 911-915
24. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., and Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 99 (2006) 392-401
25. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., and Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
26. Shi R., and Berkel H.J. Insulin-like growth factor-I and prostate cancer: a meta analysis. Br. J. Cancer 85 (2001) 991-996
27. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., and Egger M. Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
28. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., and Plymate S.R. Protein and mRNA for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 81 (1996) 3774-3782
29. Bae V.L., Jackson-Cook C.K., Brothman A.R., Maygarden S.J., and Ware J.L. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int. J. Cancer 58 (1994) 721-729
30. Bae V.L., Jackson-Cook C.K., Maygarden S.J., Plymate S.R., Chen J., and Ware J.L. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34 (1998) 275-282
31. Damon S.E., Plymate S.R., Carroll J.M., Sprenger C.C., Dechsukhum C., Ware J.L., and Roberts Jr. C.T. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142 (2001) 21-27
32. Werner H., Rauscher III F.J., Sukhatme V.P., Drummond I.A., Roberts Jr. C.T., and LeRoith D. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J. Biol. Chem. 269 (1994) 12577-12582
33. Berkovich E., and Ginsberg D. ATM is a target for positive regulation by E2F1. Oncogene 22 (2003) 161-167
34. Idelman G., Glaser T., Roberts Jr. C.T., and Werner H. WT1-p53 interactions in IGF-I receptor gene regulation. J. Biol. Chem. 278 (2003) 3474-3482
35. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61 (2001) 6276-6280
36. Young A.P., Nagarajan R., and Longmore G.D. Mechanisms of transcriptional regulation by Rb-E2F segregate by biological pathway. Oncogene 22 (2003) 7209-7217
37. Shen W.H., Yin Y., Broussard S.R., McCusker R.H., Freund G.G., Dantzer R., and Kelley K.W. Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F1 synthesis. J. Biol. Chem. 279 (2004) 7438-7446
38. Pierce A.M., Schneider-Broussard R., Gimenez-Conti I.B., Russell J.L., Conti C.J., and Johnson D.G. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol. 19 (1999) 6408-6414
39. Phillips S.M., Barton C.M., Lee S.J., Morton D.G., Wallace D.M., Lemoine N.R., and Neoptolemos J.P. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br. J. Cancer 70 (1994) 1252-1257
40. Ittmann M.M., and Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Human Pathol. 27 (1996) 28-34
41. Tricoli J.V., Gumerlock P.H., and Yao J.L. N.C.I. The cooperative prostate network, alterations of the retinoblastoma gene in human prostate adenocarcinoma. Gene Chromosome Cancer 15 (1996) 108-114
42. Brooks J.D., Bova G.S., and Isaacs W.B. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinoma. Prostate 26 (1995) 35-39
43. Ittmann M. Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res. 56 (1996) 2143-2147
44. Maddison L.A., Sutherland B.W., Barrios R., and Greenberg N.M. Conditional deletion of Rb causes early stage prostate cancer. Cancer Res. 64 (2004) 6018-6025
45. Davis J.N., Wojno K.D., Daignaultu S., Hofer M.D., Kuefer R., Rubin M.A., and Day M.L. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66 (2006) 11897-11906